Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Ophthalmologica ; 247(2): 118-132, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38408445

RESUMEN

INTRODUCTION: The objective of this study was to compare the outcome of submacular hemorrhage (SMH) displacement using pneumatic displacement with intravitreal expansile gas versus pars plana vitrectomy (PPV) with subretinal injection of tissue plasminogen activator (tPA), anti-vascular endothelial growth factor (VEGF) agent, and air as primary surgery. METHODS: Retrospective interventional case series of 63 patients who underwent surgical displacement of SMH secondary to neovascular age-related macular degeneration (nAMD) or polypoidal choroidal vasculopathy (PCV) from May 1, 2015, to October 31, 2022. Medical records were reviewed for diagnosis, logMAR visual acuity (VA), central subfield thickness (CST), and postoperative displacement rates and complications up to 12 months after operation. RESULTS: The diagnosis was nAMD in 24 (38.1%) and PCV in 39 (61.9%) eyes. There were 40 (63.5%) eyes in the pneumatic displacement group (38 received C3F8, 2 received SF6) and 23 (36.5%) eyes in the subretinal cocktail injection. Mean baseline VA was 1.46 and 1.62, respectively (p = 0.404). The subretinal injection group had more extensive SMH (p = 0.005), thicker CST (1,006.6 µm vs. 780.2 µm, p = 0.012), and longer interval between symptom and operation (10.65 vs. 5.53 days, p < 0.001). The mean postoperative VA at 6 months was 0.67 and 0.91 (p = 0.180) for pneumatic displacement and subretinal injection groups, respectively, though VA was significantly better in the pneumatic group at 12-month visit (0.64 vs. 1.03, p = 0.040). At least 10 mean change in VA were >10 letters gain in both groups up to 12 months. Postoperative CST reduction was greater (625.1 µm vs. 326.5 µm, p = 0.008) and complete foveal displacement (87.0% vs. 37.5%), p < 0.001, odds ratio [OR] = 11.1) and displacement to arcade or beyond (52.5% vs. 17.5%, p = 0.009, OR = 5.15) were more frequent in the subretinal injection group. Two patients with failed pneumatic displacement were successfully treated with subretinal cocktail injection as a second operation. CONCLUSION: Surgical displacement of SMH leads to clinically meaningful improvement in VA. PPV with subretinal cocktail injection is more effective than pneumatic displacement in displacing SMH with similar safety profile despite longer interval before operation, higher CST, and more extensive SMH at baseline. Retinal surgeons could consider this novel technique in cases with thick and extensive SMH or as a rescue secondary operation in selected cases.


Asunto(s)
Endotaponamiento , Angiografía con Fluoresceína , Hemorragia Retiniana , Activador de Tejido Plasminógeno , Tomografía de Coherencia Óptica , Agudeza Visual , Vitrectomía , Humanos , Estudios Retrospectivos , Hemorragia Retiniana/diagnóstico , Hemorragia Retiniana/terapia , Hemorragia Retiniana/etiología , Masculino , Femenino , Vitrectomía/métodos , Anciano , Endotaponamiento/métodos , Activador de Tejido Plasminógeno/administración & dosificación , Tomografía de Coherencia Óptica/métodos , Angiografía con Fluoresceína/métodos , Inyecciones Intravítreas , Inhibidores de la Angiogénesis/administración & dosificación , Estudios de Seguimiento , Resultado del Tratamiento , Degeneración Macular Húmeda/diagnóstico , Degeneración Macular Húmeda/terapia , Degeneración Macular Húmeda/complicaciones , Fondo de Ojo , Fibrinolíticos/administración & dosificación , Fluorocarburos/administración & dosificación , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Anciano de 80 o más Años , Persona de Mediana Edad , Hexafluoruro de Azufre/administración & dosificación
2.
Graefes Arch Clin Exp Ophthalmol ; 253(12): 2075-85, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25619667

RESUMEN

PURPOSE: We aimed to evaluate the long-term natural history of polypoidal choroidal vasculopathy (PCV) in untreated patients. METHODS: This is a retrospective observational case series. Patients with symptomatic PCV who did not receive any treatment for at least 12 months were included from the records of three ophthalmic clinics in Asia. The medical records and imaging data were reviewed. Visual outcomes at month 12 and at last follow-up were analyzed. The influence of demographics and presenting features on visual outcome was analyzed. RESULTS: A total of 32 eyes (32 patients) were included in this analysis. The mean follow-up was 59.9 months (range, 18-119 months), the mean age was 65.7 years and 21 (65.6 %) patients were male. The mean presenting logMAR visual acuity was 0.79 (Standard deviation [SD] 0.49). The center of the fovea was involved by the PCV complex in 25 eyes (78.1 %). The mean greatest linear dimension (GLD) of the PCV complex was 2584 µm (SD 880). Twenty-three eyes (71.9 %) had a cluster-of-grapes configuration on indocyanine green angiography. Leakage of fluorescein angiography was present in 29 eyes (90.6 %). The mean logMAR vision deteriorated from 0.79 at baseline to 0.88 at month 12 (p = 0.11), and further to 1.14 (p = 0.003) at the last follow-up. The proportion of eyes that improved, remained unchanged and worsened was 21.9 %, 31.3 % and 46.9 %, respectively, at month 12; and 28.1 %, 9.4 % and 62.5 %, respectively, at last follow-up. The proportion of eyes with logMAR vision worse than 1.0 was 28.1 % at presentation, and increased to 31.3 % at month 12 and further to 53.1 % at last follow-up. Reasons for poor vision were due to retinal, subretinal or vitreous hemorrhage, and retinal pigment epithelium (RPE) atrophy and scarring. None of the presenting features were found to significantly influence visual outcome. CONCLUSIONS: Half of eyes presenting with symptomatic PCV had a relatively benign course without treatment and some even had vision improvement. However, in the remaining eyes, vision deteriorated significantly, mainly due to hemorrhage and scarring. There may be subtypes of PCV with divergent natural history.


Asunto(s)
Neovascularización Coroidal/diagnóstico , Pólipos/diagnóstico , Anciano , Pueblo Asiatico/etnología , Neovascularización Coroidal/etnología , Neovascularización Coroidal/fisiopatología , Colorantes/administración & dosificación , Femenino , Angiografía con Fluoresceína , Estudios de Seguimiento , Humanos , Verde de Indocianina/administración & dosificación , Masculino , Persona de Mediana Edad , Pólipos/etnología , Pólipos/fisiopatología , Estudios Retrospectivos , Agudeza Visual/fisiología
3.
Retina ; 31(8): 1581-8, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21610566

RESUMEN

PURPOSE: To evaluate the efficacy of intravitreal ranibizumab with or without verteporfin photodynamic therapy (PDT) in the treatment of symptomatic polypoidal choroidal vasculopathy. METHODS: Twenty-three eyes of 23 patients received 3 monthly intravitreal ranibizumab injections with or without indocyanine green angiography-guided PDT at baseline. All patients had follow-up of ≥12 months. Visual and anatomical outcomes were compared between the two groups and a PDT monotherapy group. RESULTS: Seven eyes had ranibizumab monotherapy, 16 had combined ranibizumab injections and verteporfin PDT, and 12 had PDT monotherapy. At 3 months, the mean logarithm of minimal angle of resolution best-corrected visual acuity improved from 0.92 to 0.74 in the ranibizumab group (P = 0.18), from 0.70 to 0.59 in the combined group (P = 0.037), and from 0.74 to 0.57 in the PDT monotherapy group (P = 0.014). Complete regression of polypoidal lesions in indocyanine green angiography was found in 1 (14.3%) eye in the ranibizumab group, compared with 15 (93.8%) eyes in the combined group (P = 0.001). Additional PDT and ranibizumab injections in eyes with persistent polyps and fluorescein leakage resulted in regression of polyps in all eyes. At 12 months, no significant difference in logarithm of minimal angle of resolution best-corrected visual acuity and visual change was found between eyes initially treated with ranibizumab monotherapy, combined ranibizumab and PDT, or PDT monotherapy (P = 1.00 and P = 0.11, respectively). CONCLUSION: Intravitreal ranibizumab appeared to result in stabilization of vision in patients with symptomatic polypoidal choroidal vasculopathy. However, combined ranibizumab and PDT appeared to be more effective in causing complete regression of the polypoidal lesions in indocyanine green angiography compared with ranibizumab monotherapy.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Enfermedades de la Coroides/tratamiento farmacológico , Enfermedades Vasculares Periféricas/tratamiento farmacológico , Fotoquimioterapia , Anciano , Anciano de 80 o más Años , Coroides/irrigación sanguínea , Enfermedades de la Coroides/diagnóstico , Enfermedades de la Coroides/fisiopatología , Colorantes , Terapia Combinada , Femenino , Angiografía con Fluoresceína , Estudios de Seguimiento , Humanos , Verde de Indocianina , Inyecciones Intravítreas , Masculino , Persona de Mediana Edad , Enfermedades Vasculares Periféricas/diagnóstico , Enfermedades Vasculares Periféricas/fisiopatología , Ranibizumab , Estudios Retrospectivos , Resultado del Tratamiento , Agudeza Visual/fisiología
4.
Invest Ophthalmol Vis Sci ; 48(12): 5499-504, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18055798

RESUMEN

PURPOSE: To determine the repeatability and reproducibility of central and peripheral corneal pachymetry mapping with anterior segment-optical coherence tomography (AS-OCT). METHODS: An observational cross-sectional study involving two groups: 27 healthy eyes and 20 eyes with keratoconus. Each subject underwent scanning sessions with AS-OCT to determine intraobserver repeatability, interobserver reproducibility, and additionally for healthy eyes, intersession reproducibility for different regions of the cornea up to a 10-mm diameter. Main outcome measures were reproducibility and repeatability coefficients, intraclass correlation coefficients, and coefficients of variation of the average central (0-2 mm), pericentral (2-5 mm), transitional (5-7 mm), and peripheral (7-10 mm) corneal thicknesses generated by the Visante AS-OCT (Carl Zeiss Meditec, Inc., Dublin, CA) pachymetric mapping protocol. RESULTS: The coefficients of repeatability were less than 2% in healthy subjects and less than 3% in patients with keratoconus. The reproducibility coefficients were less than 2% and 4% in healthy subjects and patients with keratoconus, respectively. There was no significant difference between scans obtained by different observers or during different visits. The intraclass correlation coefficients were greater than 0.99 and 0.97 in healthy subjects and patients with keratoconus, respectively. CONCLUSIONS: With the pachymetric mapping protocol of Visante AS-OCT, these results suggest that central and peripheral corneal thickness measurements in healthy subjects and in eyes with keratoconus are repeatable and reproducible.


Asunto(s)
Córnea/patología , Queratocono/diagnóstico , Tomografía de Coherencia Óptica/métodos , Adolescente , Adulto , Anciano , Pesos y Medidas Corporales , Córnea/anatomía & histología , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Reproducibilidad de los Resultados , Tomografía de Coherencia Óptica/instrumentación
5.
Sci Rep ; 6: 27082, 2016 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-27256987

RESUMEN

We report our experience with the use of intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). A retrospective review was performed on 138 consecutive infants screened at a single centre over 18 months. Intravitreal ranibizumab was offered in selected cases requiring treatment, such as aggressive posterior ROP or poor mydriasis. 2 eyes of 1 infant received intravitreal ranibizumab alone and 8 eyes of 5 infants received combined intravitreal ranibizumab and laser therapy. 3 out of 8 eyes treated initially with intravitreal ranibizumab monotherapy had persistent disease requiring laser therapy, and 3 out of 5 eyes with initial regression suffered disease recurrence at a mean of 7.6 weeks post-injection. 2 eyes treated first with laser followed by intravitreal ranibizumab had disease regression without recurrence. Our cohort demonstrate a significant rate of persistent disease and recurrence in ROP eyes treated initially with intravitreal ranibizumab monotherapy, which is greater and earlier than that reported for intravitreal bevacizumab in the BEAT-ROP study. Intravitreal ranibizumab may be useful as an initial treatment in selected cases of ROP when laser therapy as first line is suboptimal. However, close monitoring is important and adjunctive laser therapy may subsequently be needed in a majority of cases.


Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Terapia por Láser/métodos , Ranibizumab/uso terapéutico , Retina/efectos de los fármacos , Retinopatía de la Prematuridad/tratamiento farmacológico , Bevacizumab/uso terapéutico , Terapia Combinada , Femenino , Edad Gestacional , Humanos , Lactante , Recien Nacido con Peso al Nacer Extremadamente Bajo , Recién Nacido , Recien Nacido Prematuro , Inyecciones Intravítreas , Masculino , Recurrencia , Retina/patología , Retina/cirugía , Retinopatía de la Prematuridad/metabolismo , Retinopatía de la Prematuridad/patología , Retinopatía de la Prematuridad/cirugía , Estudios Retrospectivos , Riesgo , Resultado del Tratamiento
7.
Case Rep Ophthalmol ; 3(1): 1-4, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22308115

RESUMEN

PURPOSE: To report a case of a large anterior retinal capillary hemangioma (RCH) treated successfully with photodynamic therapy (PDT). METHODS: Case report. RESULTS: A 12-mm-large RCH located in the anterior retina, with vision-threatening exudative complications that had not responded to cryotherapy and repeated laser photocoagulations, was treated with PDT using verteporfin. Exudation regressed and tumor growth arrested after treatment. CONCLUSION: PDT can be delivered effectively to a lesion in the anterior retina and should be included as an option for treating anteriorly located RCH when conventional cryotherapy and laser photocoagulation fail.

8.
Invest Ophthalmol Vis Sci ; 50(12): 5596-600, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19628738

RESUMEN

PURPOSE: To investigate the association of single-nucleotide polymorphisms (SNPs) in the manganese superoxide dismutase (MnSOD) and two chemokine genes (CCL2 and CCL5) in patients with anterior uveitis (AU). METHODS: Seventy-nine Chinese patients with acute AU were recruited, and genotyping of four SNPs including MnSOD 47, CCL2 -2518, CCL2 -2076, and CCL5 -403 alleles was performed with SNP genotyping assays. The genotype and allele frequencies were compared between patients with AU and 206 healthy control subjects. Analyses were also stratified according to the HLA-B27 status of the patients. RESULTS: There were significant increases in the frequency of the AA homozygosity in the MnSOD 47 SNP (P = 0.049) and in the CCL2 -2518G allele frequency and GG homozygosity in patients with AU compared with control subjects (P = 0.017 and P = 0.024, respectively). No significant association was found between AU with the CCL2 -2076 and CCL5 -403 SNPs. Subgroup analyses showed that the MnSOD 47A polymorphism was significantly associated with AU in HLA-B27-positive patients, but not in HLA-B27-negative patients, whereas the CCL2 -2518G polymorphism was significantly associated with AU in HLA-B27-negative patients, but not in HLA-B27-positive patients. CONCLUSIONS: The 47A polymorphism in the MnSOD gene and the -2518G polymorphism in the CCL2 gene are associated with the development of AU in HLA-B27-positive and -negative Chinese patients, respectively. Further studies to evaluate the interactions of the HLA-B27 status and these SNPs are warranted.


Asunto(s)
Quimiocina CCL2/genética , Quimiocina CCL5/genética , Polimorfismo de Nucleótido Simple , Superóxido Dismutasa/genética , Uveítis Anterior/genética , Enfermedad Aguda , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Pueblo Asiatico/genética , Estudios de Casos y Controles , Femenino , Frecuencia de los Genes , Genotipo , Antígeno HLA-B27/genética , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Adulto Joven
9.
Graefes Arch Clin Exp Ophthalmol ; 245(8): 1225-7, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17287977

RESUMEN

BACKGROUND: To report the development of retinal pigment epithelial (RPE) tear after intravitreal injection of ranibizumab (Lucentis, Novartis, Basel, Switzerland). METHODS: Case report with presentation of the fundus photography, fluorescein angiography (FA) and optical coherence tomography (OCT) findings. RESULTS: A 70-year-old man received intravitreal injections of ranibizumab for the treatment of occult choroidal neovascularisation (CNV) with fibrovascular pigment epithelial detachment due to age-related macular degeneration. One day after the third intravitreal ranibizumab injection, fundus examination showed a RPE defect at the foveal region. FA and OCT confirmed the presence of RPE tear sparing the fovea. No further progression of the RPE tear was observed after withholding subsequent ranibizumab injection and his right eye visual acuity remained at 20/100 at 3 months from the last injection. CONCLUSIONS: As with other anti-vascular endothelial growth factor treatment for CNV, RPE tear might occur after intravitreal ranibizumab injection even after previous uneventful intravitreal injections.


Asunto(s)
Inhibidores de la Angiogénesis/efectos adversos , Anticuerpos Monoclonales/efectos adversos , Neovascularización Coroidal/tratamiento farmacológico , Degeneración Macular/tratamiento farmacológico , Epitelio Pigmentado Ocular/efectos de los fármacos , Perforaciones de la Retina/etiología , Enfermedad Aguda , Anciano , Anticuerpos Monoclonales Humanizados , Angiografía con Fluoresceína , Humanos , Inyecciones , Masculino , Epitelio Pigmentado Ocular/patología , Ranibizumab , Perforaciones de la Retina/diagnóstico , Tomografía de Coherencia Óptica , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Cuerpo Vítreo
10.
Ophthalmologica ; 221(1): 24-8, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17183197

RESUMEN

BACKGROUND: To evaluate the safety and efficacy of micro-incisional cataract surgery (MICS) with bimanual phacoemulsification for the management of white mature cataract. METHODS: Twenty-five eyes in 25 patients with mature cataract were prospectively recruited to undergo MICS with bimanual phacoemulsification. Serial changes in best-corrected visual acuity (BCVA), central corneal thickness (CCT) and endothelial cell density (ECD) were compared using the Wilcoxon signed-rank test. RESULTS: MICS was successfully performed in 24 (96%) of the 25 eyes, with 1 eye requiring conversion to extracapsular cataract extraction due to radial tear during continuous curvilinear capsulorhexis. The median preoperative BCVA was hand movement. On day 1 postoperatively, the median BCVA improved to 0.6 (p < 0.001 compared with baseline). All patients had BCVA of 0.6 or better at 3 months after surgery (p < 0.001 compared with baseline). The mean increase in CCT at day 1 and week 1 postoperatively was 11.5 and 7.1%, respectively. The change in mean CCT was no longer significant at month 3 postoperatively (p = 0.82). The mean reduction in ECD at 3 months postoperatively was 7.8% (p = 0.037). None of the patients developed any postoperative complications. CONCLUSIONS: MICS with bimanual phacoemulsification appeared to be a promising alterative for the management of white mature cataract.


Asunto(s)
Catarata/patología , Facoemulsificación/métodos , Anciano , Humanos , Complicaciones Intraoperatorias , Implantación de Lentes Intraoculares , Microcirugia/efectos adversos , Microcirugia/métodos , Persona de Mediana Edad , Facoemulsificación/efectos adversos , Complicaciones Posoperatorias , Estudios Prospectivos , Agudeza Visual/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA